AlphaCentric Advisors »

Halozyme Therapeutics shares owned by AlphaCentric Advisors

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by AlphaCentric Advisors from 13F filings

Historical chart of AlphaCentric Advisors investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by AlphaCentric Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by AlphaCentric Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $305k 4.5k 67.30

More positions owned by AlphaCentric Advisors

Gilead Sciences (GILD)
Invitation Homes (INVH)
Ishares Tr Mbs Etf (MBB)
Euronet Worldwide (EEFT)
Vertex Pharmaceuticals Incorporated (VRTX)
Astrazeneca Sponsored Adr
Alpine Income Ppty Tr (PINE)
Invesco Exchange Traded Fd T S&p500 Pur Val (RPV)
Ishares Tr Rus 1000 Val Etf (IWD)
Ionis Pharmaceuticals (IONS)
Stereotaxis Com New (STXS)
Incyte Corporation (INCY)
Insmed Com Par $.01 (INSM)
AMREP Corporation (AXR)
Argenx Se Sponsored Adr (ARGX)

View all positions for AlphaCentric Advisors

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Invesco
Arrowstreet Capital, Limited Partnership
D. E. Shaw & Co
Geode Capital Management
Snyder Capital Management
Dimensional Fund Advisors
Alliancebernstein
Norges Bank Investment Management
William Blair Investment Management
Federated Investors
Jupiter Asset Management
Wells Fargo & Company

View all funds holding Halozyme Therapeutics